Glenmark Pharma

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

The tech platform said producers can better detect contamination and allergens with its program in order to achieve compliance.

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross domestic product. McKinsey & Co. follows suit, noting AI could generate 30% efficiency gains and cost savings in the pharmaceutical sector and trigger financial gains of up to $110 billion annually.

InterContinental Beverage Capital held its Annual Partners Meeting reflecting on 2024's industry trends and outlining its 2025 strategy. Key insights included the rise of functional beverages, AI's impact,

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases offering training for it.

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare industry. Just last month, AWS and General Catalyst announced their partnership to speed up the development and deployment of healthcare AI tools.

Technological innovations in steam power, electricity and microprocessors drove the first industrial revolution.

Isomorphic was spun out of Google's AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up's potential has attracted big pharmaceutical partners, which are keen to lower expenses and boost efficiency of the costly drug development process.